Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercializing the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is $171m (vs $136m previously).
02 Aug 2016
Progress with R&D and commercialization
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progress with R&D and commercialization
Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercializing the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is $171m (vs $136m previously).